 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Presentation on Tuesday, September 12, 2023 at 3:00pm EDT TARRYTOWN, NY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of ...

PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PaxMedica, Inc. (NASDAQ:PXMD  Get Free Report) Director Zachary Rome sold 20,000 shares of the firms stock in a transaction dated Monday, August 21st. The shares were sold at an average...

Zachary Rome Sells 20,000 Shares of PaxMedica, Inc. (NASDAQ:PXMD) Stock

Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) ...

PaxMedica Appoints David Hough M.D. as Chief Medical Officer

Paxmedica reports Q2 results

TARRYTOWN, NY, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, today provided a...

PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update

The studys primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing an NDA for the use of PAX-101 (intravenous suramin) for the treatment of African Sleeping Sickness TARRYTOWN, NY, July 24, 2023 (GLOBE NEWSWIRE...

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

PaxMedica parasite drug suramin phase 3 trial achieves survival benefit

Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as well as additional offerings for People diagnosed with Autism and their Families TARRYTOWN, NY and HUDSON, OH, ...

PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC

Engages ShareIntel to Track Market Activity TARRYTOWN, NY, June 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum ...

PaxMedica Comments on Common Stock Volatility

Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder...

PaxMedica CEO Interviewed by The BRAIN Foundation

PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.

Watchers	3,583
52-Wk Low	$0.2537
52-Wk High	$4.07

Market Cap	$5.2M
Volume (M)	47,863.00
52-Wk High	$4.07
52-Wk Low	$0.2537

PXMD PaxMedica, Inc.

About

Feed

News

Earnings

Fundamentals